Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications. MZE001, designed and developed by Maze, is an oral GYS1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen accumulation. Under the terms of the agreement, Maze will receive a $150M payment consisting of both upfront cash and future equity investment for the rights to further develop and commercialize MZE001, as well as an exclusive license to related GYS1-targeting back-up programs and intellectual property. Maze will be eligible to receive up to an additional approximately $600M in potential development, regulatory and sales milestones, as well as meaningful royalties on sales if MZE001 is successfully commercialized.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Sanofi downgraded to Sell from Hold at Deutsche Bank
- Sanofi completes acquisition of Provention Bio
- Sanofi confirms FY23 business EPS view of up low single digits at CER
- Sanofi reports Q1 business EPS EUR 2.16, up 11.9% at CER
- Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention
